EMAIL THIS PAGE TO A FRIEND

Biochemical and biophysical research communications

Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells.


PMID 25721666

Abstract

In diabetes mellitus (DM), high glucose (HG) and advanced glycation end products (AGEs) are involved in bone quality deterioration. Osteocytes produce sclerostin and receptor activator of nuclear factor-кB ligand (RANKL) and regulate osteoblast and osteoclast function. However, whether HG or AGEs directly affect osteocytes and regulate sclerostin and RANKL production is unknown. Here, we examined the effects of HG, AGE2, and AGE3 on the expression of sclerostin and RANKL and on apoptosis in osteocyte-like MLO-Y4-A2 cells. Treatment of the cells with 22xa0mM glucose, 100xa0μg/mL either AGE2 or AGE3 significantly increased the expression of sclerostin protein and mRNA; however, both AGEs, but not glucose, significantly decreased the expression of RANKL protein and mRNA. Moreover, treatment of the cells with HG, AGE2, or AGE3 for 72xa0h induced significant apoptosis. These detrimental effects of HG, AGE2, and AGE3 on sclerostin and RANKL expressions and on apoptosis were antagonized by pretreatment of the cells with 10(-8)xa0M human parathyroid hormone (PTH)-(1-34). Thus, HG and AGEs likely suppress bone formation by increasing sclerostin expression in osteocytes, whereas AGEs suppress bone resorption by decreasing RANKL expression. Together, these processes may cause low bone turnover in DM. In addition, HG and AGEs may cause cortical bone deterioration by inducing osteocyte apoptosis. PTH may effectively treat these pathological processes and improve osteocyte function.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

AV41642
Anti-AGER (AB1) antibody produced in rabbit, affinity isolated antibody
AV41643
Anti-AGER (AB2) antibody produced in rabbit, IgG fraction of antiserum
SAB2104808
Anti-AGER, (N-terminal) antibody produced in rabbit, affinity isolated antibody
R5278 Anti-RAGE (Receptor for Advanced Glycation Endproducts) antibody produced in rabbit, affinity isolated antibody
SAB1401326
Anti-RAGE antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB2105049
Anti-RAGE, (N-terminal) antibody produced in rabbit, affinity isolated antibody
SAB1300753
Anti-SOST (center) antibody produced in rabbit, Ig fraction of antiserum, buffered aqueous solution
SAB1307104
ANTI-SOST (CENTER) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1300086
Anti-SOST (N-term) antibody produced in rabbit, Ig fraction of antiserum, buffered aqueous solution
SAB1307103
ANTI-SOST(N-TERMINAL) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1306836
ANTI-SOST(N-TERMINAL) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB1409922
Anti-TNFSF11 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB4503430
Anti-TNFSF11 antibody produced in rabbit, affinity isolated antibody
SAB1411542
Anti-TNFSF11 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
EHU123971 MISSION® esiRNA, esiRNA human RAGE (esiRNA1)
SAB1403530
Monoclonal Anti-AGER, (C-terminal) antibody produced in mouse, clone 1C1, purified immunoglobulin, buffered aqueous solution
SAB1402993
Monoclonal Anti-TNFSF11, (C-terminal) antibody produced in mouse, clone 3F7, purified immunoglobulin, buffered aqueous solution
T2942 Monoclonal Anti-TRANCE antibody produced in mouse, clone 70525, purified immunoglobulin, lyophilized powder